Los puntos clave no están disponibles para este artículo en este momento.
Key Points Gilteritinib induces 2 distinct marrow responses in FLT3-mutated AML: responses with and without differentiation. Ongoing clonal hematopoiesis is ubiquitous during gilteritinib therapy and may promote genetic evolution and drug resistance.
McMahon et al. (Thu,) studied this question.